A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
A decay in intracellular NAD+ levels is one of the hallmarks of physiological decline in normal tissue functions. Accordingly, dietary supplementation with NAD+ precursors can prevent, alleviate, or even reverse multiple metabolic complications and age-related disorders in diverse model organisms. Within the constellation of NAD+ precursors, nicotinamide riboside (NR) has gained attention due to its potent NAD+ biosynthetic effects in vivo while lacking adverse clinical effects. Nevertheless, NR is not stable in circulation, and its utilization is rate-limited by the expression of nicotinamide riboside kinases (NRKs). Therefore, there is a strong interest in identifying new effective NAD+ precursors that can overcome these limitations. Through a combination of metabolomics and pharmacological approaches, we describe how NRH, a reduced form of NR, serves as a potent NAD+ precursor in mammalian cells and mice. NRH acts as a more potent and faster NAD+ precursor than NR in mammalian cells and tissues. Despite the minor structural difference, we found that NRH uses different steps and enzymes to synthesize NAD+, thus revealing a new NRK1-independent pathway for NAD+ synthesis. Finally, we provide evidence that NRH is orally bioavailable in mice and prevents cisplatin-induced acute kidney injury. Our data identify a new pathway for NAD+ synthesis and classify NRH as a promising new therapeutic strategy to enhance NAD+ levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“NADþ also acts as a degradation substrate for multiple enzymes such as the sirtuin family of protein deacylases [2], poly (ADP-ribose) polymerases [3], and ADP-ribose cyclases [4].”
BackgroundCantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648
Self-citationNAD + repletion improves mitochondrial and stem cell function and enhances life span in mice
Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., D’Amico, D., Ropelle, E. R., Lutolf, M. P., Aebersold, R., et al. (2016) · Science · doi:10.1126/science.aaf2693 · Cited by 1,255 · cited 1×
“Similarly, both compounds afforded protection against age-related physiological decline in mice [16,17].”
Cantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238
Self-citationMouchiroud, L., Houtkooper, R. H., Moullan, N., Katsyuba, E., Ryu, D., Cantó, C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.016 · Cited by 1,210
Self-citationMills, K. F., Yoshida, S., Stein, L. R., Grozio, A., Kubota, S., Sasaki, Y., Redpath, P., Migaud, M. E., Apte, R. S., Uchida, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.013 · Cited by 930 · cited 1×
“Similarly, both compounds afforded protection against age-related physiological decline in mice [16,17].”
Self-citationBieganowski, P., & Brenner, C. (2004) · Cell · doi:10.1016/s0092-8674(04)00416-7 · Cited by 750
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016) · Nature Communications · doi:10.1038/ncomms12948 · Cited by 697 · cited 2×
“Accordingly, NAM levels in plasma, as well as those of NAM methylation and oxidation products, increase shortly after NR administration [18,22].”
BackgroundSelf-citationMartens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018) · Nature Communications · doi:10.1038/s41467-018-03421-7 · Cited by 588
Quantitative Analysis of NAD Synthesis-Breakdown Fluxes
Liu, L., Su, X., Quinn, W. J., Hui, S., Krukenberg, K., Frederick, D. W., Redpath, P., Zhan, L., Chellappa, K., White, E., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.018 · Cited by 564
Self-citation
Research works printed but not linked: 22
- Chambon, 1963, Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme, Biochemical and Biophysical Research Communications, 1139
- Lee, 1991, ADP-ribosyl cyclase: an enzyme that cyclizes NAD+ into a calcium-mobilizing metabolite, Cell Regulation, 2, 203, 10.1091/mbc.2.3.203 · DOI · Paper page
- Belenky, 2007, NAD+ metabolism in health and disease, Trends in Biochemical Sciences, 32, 12, 10.1016/j.tibs.2006.11.006 · DOI · Paper page
- Benyo, 2005, GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing, Journal of Clinical Investigation, 115, 3634, 10.1172/JCI23626 · DOI · Paper page
- Soga, 2003, Molecular identification of nicotinic acid receptor, Biochemical and Biophysical Research Communications, 303, 364, 10.1016/S0006-291X(03)00342-5 · DOI · Paper page
- Tunaru, 2003, PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect, Nature Medicine, 9, 352, 10.1038/nm824 · DOI · Paper page
- Wise, 2003, Molecular identification of high and low affinity receptors for nicotinic acid, Journal of Biological Chemistry, 278, 9869, 10.1074/jbc.M210695200 · DOI · Paper page
- Yoshino, 2011, Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice, Cell Metabolism, 14, 528, 10.1016/j.cmet.2011.08.014 · DOI · Paper page
- Nikiforov, 2011, Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation, Journal of Biological Chemistry, 286, 21767, 10.1074/jbc.M110.213298 · DOI · Paper page
- Dolopikou, 2019, Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study, European Journal of Nutrition
- Ramesh, 2014, Mouse models and methods for studying human disease, acute kidney injury (AKI), Methods in Molecular Biology, 1194421
- Wong, 2002, Identification of N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-pyridone-5-carboxamide as components in urine extracts of individuals consuming coffee, Journal of Pharmaceutical and Biomedical Analysis, 30, 773, 10.1016/S0731-7085(02)00384-9 · DOI
- Makarov, 2019, Syntheses and chemical properties of beta-nicotinamide riboside and its analogues and derivatives, Beilstein Journal of Organic Chemistry, 15401
- Tran, 2016, PGC1alpha drives NAD biosynthesis linking oxidative metabolism to renal protection, Nature, 531, 528, 10.1038/nature17184 · DOI · Paper page
- Poyan Mehr, 2018, De novo NAD+ biosynthetic impairment in acute kidney injury in humans, Nature Medicine, 24, 1351, 10.1038/s41591-018-0138-z · DOI · Paper page
- Ozkok, 2014, Pathophysiology of cisplatin-induced acute kidney injury, BioMed Research International, 2014967826
- Miller, 2010, Mechanisms of cisplatin nephrotoxicity, Toxins (Basel), 2, 2490, 10.3390/toxins2112490 · DOI · Paper page
- Mandic, 2003, Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling, Journal of Biological Chemistry, 278, 9100, 10.1074/jbc.M210284200 · DOI · Paper page
- Bottinger, 2002, TGF-beta signaling in renal disease, Journal of the American Society of Nephrology, 13, 2600, 10.1097/01.ASN.0000033611.79556.AE · DOI · Paper page
- Yang, 2019, Dihydronicotinamide riboside is a potent NAD+ concentration enhancer in vitro and in vivo, Journal of Biological Chemistry, 10.1074/jbc.RA118.005772 · DOI · Paper page
- Kulikova, 2015, Generation, release, and uptake of the NAD precursor nicotinic acid riboside by human cells, Journal of Biological Chemistry, 290, 27124, 10.1074/jbc.M115.664458 · DOI · Paper page
- Katsyuba, 2018, De novo NAD+ synthesis enhances mitochondrial function and improves health, Nature, 563, 354, 10.1038/s41586-018-0645-6 · DOI · Paper page
Cited by
NAD+ metabolism and its roles in cellular processes during ageing
Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00313-x · Cited by 1,617
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
Evolving concepts in NAD+ metabolism
Chini, C. C. S., Zeidler, J. D., Kashyap, S., Warner, G., & Chini, E. N. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.003 · Cited by 288
NAD precursors cycle between host tissues and the gut microbiome
Chellappa, K., McReynolds, M. R., Lu, W., Zeng, X., Makarov, M., Hayat, F., Mukherjee, S., Bhat, Y. R., Lingala, S. R., Shima, R. T., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.004 · Cited by 146
Self-citationAlegre, G. F. S., & Pastore, G. M. (2023) · Current Nutrition Reports · doi:10.1007/s13668-023-00475-y · Cited by 101
Metadata
- Authors
- Giroud-Gerbetant, J., Joffraud, M., Giner, M. P., Cercillieux, A., Bartova, S., Makarov, M. V., Zapata-Pérez, R., Sánchez-García, J. L., Houtkooper, R. H., Migaud, M. E., Moco, S., & Canto, C.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 30
- Pages
- 192-202
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W2978252541
- Cited by
- 129
- References
- 19
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Institutes of Health (AT009908-01)
- Fundación Séneca
- Horizon 2020 Framework Programme
- École Polytechnique Fédérale de Lausanne
- Horizon 2020 (840110)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor. https://app.cochat.ai/papers/10.1016/j.molmet.2019.09.013
- The paper
- Giroud-Gerbetant, J., Joffraud, M., Giner, M. P., Cercillieux, A., Bartova, S., Makarov, M. V., Zapata-Pérez, R., Sánchez-García, J. L., Houtkooper, R. H., Migaud, M. E., Moco, S., & Canto, C. (2019). A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor. Molecular Metabolism. https://doi.org/10.1016/j.molmet.2019.09.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.